Scancell to present at 20th SMR Congress
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that data from the first stage in its Phase 2 SCOPE trial, investigating SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma, was presented at the 20th International Congress of the Society for Melanoma Research which took place on 6-9 November 2023 in Philadelphia, PA.
The title, timing and location of the presentation are as follows:
Poster presentation title A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab+ ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE trial
Presenting Author Fayaz Master
Session name Late breaking Clinical Abstracts
Session date and time 11:00am - 11:15am EDT, Thursday November 9th, 2023
The abstract of the presentation will be made available on Scancell's website at: https://www.scancell.co.uk/vaccine-publications
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.